WALL STREET STOCKS MARION LABS MKC NEW YORK April Marion Laboratories Inc s stock rose sharply today after the company presented a bullish earnings scenario at a meeting for pharmaceutical analysts Monday traders and analysts said The company said it expects earnings for fiscal ending June to rise more than pct over a year ago That pronouncement encouraged analyst David Crossen of Sanford C Bernstein and Co to raise his earnings estimates for the company to dlrs a share in compared to his previous estimate of dlrs a share Last year the company earned cts a share Marion s stock gained to At the meeting of pharmaceutical analysts Marion s president Fred Lyons Jr said Wall Street eanrings estimates of dlrs a share for fiscal are expected to cause even the aggressive side of this range to be to cts low Lyons said the strong performance in the second half of this year will result from the fourth quarter introduction of mg and mg Cardizem tablets Analyst Crossen said that Cardizem which treats angina is also expected to be approved for the treatment of hypertension by the end of the year Crossen said because Marion is still just a small company the growth of Cardizem is having a big impact on the bottom line He raised fiscal earnings estimates to dlrs a share from his previous estimate of dlrs a share The company has a broad new product pipeline in the industry and as far as I am concerned it is the most innovative company in the business he said For the five years through Crossen expects Marion to have a growth rate of pct Reuter